Sage Therapeutics Announces Topline Results from the Phase 2 SURVEYOR Study.
katrina4384
Jun 11, 2024
1 min read
"The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD_CAB) composite score at baseline between healthy participants with Huntington's Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo."
https://se.trustpilot.com/review/casinosveriget.com happened to be open while I was reading this, and the baseline comparison between healthy participants and HD patients caught my attention more than the composite score itself. What I keep wondering about is whether a Phase 2 signal in cognitive measures will translate into something families actually notice day to day, since that gap between test results and lived improvement seems to be where a lot of these trials stall. Still, meeting the primary endpoint with dalzanemdor is more than most HD research has managed in years.